Journey Medical Corporation

7.94-0.19 (-2.34%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · DERM · USD

Upcoming Earnings

Report date
Nov 12, 2025 (in 13 days)

Key Stats

Market Cap
208.90M
P/E (TTM)
-
Basic EPS (TTM)
-0.37
Dividend Yield
0%

Recent Filings

About

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

CEO
Dr. Lindsay Allan Rosenwald M.D.
IPO
11/12/2021
Employees
41
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic